The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Open accessAbstract
BACKGROUND: Current drugs for myeloproliferative neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions. Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase. METHODS: We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in patients with high-risk or intermediate-2-risk myelofibrosis. Imetelstat was administered as a 2-hour intravenous infusion (starting dose, 9.4 mg per kilogram of body weight) every 1 to 3 weeks. The primary end point was the overall response rate, and the secondary end points were adverse events, spleen response, and independence from red-cell transfusions. RESULTS: A total of 33 patients (median age, 67 years) met the eligibility criteria; 48% had received prior JAK inhibitor therapy. A complete or partial remission occurred in 7 patients (21%), with a median duration of response of 18 months (range, 13 to 20+) for complete responses and 10 months (range, 7 to 10+) for partial responses. Bone marrow fibrosis was reversed in all 4 patients who had a complete response, and a molecular response occurred in 3 of the 4 patients. Response rates were 27% among patients with a JAK2 mutation versus 0% among those without a JAK2 mutation (P=0.30) and 32% among patients without an ASXL1 mutation versus 0% among those with an ASXL1 mutation (P=0.07). The rate of complete response was 38% among patients with a mutation in SF3B1 or U2AF1 versus 4% among patients without a mutation in these genes (P=0.04). Responses did not correlate with baseline telomere length. Treatment-related adverse events included grade 4 thrombocytopenia (in 18% of patients), grade 4 neutropenia (in 12%), grade 3 anemia (in 30%), and grade 1 or 2 elevation in levels of total bilirubin (in 12%), alkaline phosphatase (in 21%), and aspartate aminotransferase (in 27%). CONCLUSIONS: Imetelstat was found to be active in patients with myelofibrosis but also had the potential to cause clinically significant myelosuppression. (Funded by Geron; ClinicalTrials.gov number, NCT01731951.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationIdentification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
A highly conserved repetitive DNA sequence,(TTAGGG) n, present at the telomeres of human chromosomes
Moyzis, R. K., Buckingham, J. M., Cram, L. S., Dani, M., Deaven, L. L., Jones, M. D., Meyne, J., Ratliff, R. L., & Wu, J. R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6622 · Cited by 1,820
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Morin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495
Greider, C. W., & Blackburn, E. H. (1987) · Cell · doi:10.1016/0092-8674(87)90576-9 · Cited by 1,150
Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationTelomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging
Blackburn, E. H., Greider, C. W., & Szostak, J. W. (2006) · Nature Medicine · doi:10.1038/nm1006-1133 · Cited by 880
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationEuropean consensus on grading bone marrow fibrosis and assessment of cellularity.
Thiele, J., Kvasnicka, H. M., Facchetti, F., Franco, V., van der Walt, J. D., & Orazi, A. (2005) · PubMed · Cited by 762
Telomerase modulates Wnt signalling by association with target gene chromatin
Park, J.-I., Venteicher, A. S., Hong, J. Y., Choi, J., Jun, S., Shkreli, M., Chang, W., Meng, Z., Cheung, P., Ji, H., et al. (2009) · Nature · doi:10.1038/nature08137 · Cited by 707
Barosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationSafety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Self-citationTefferi, A., Cervantes, F., Mesa, R., Passamonti, F., Verstovsek, S., Vannucchi, A. M., Gotlib, J., Dupriez, B., Pardanani, A., Harrison, C., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488098 · Cited by 386
Self-citationAn RNA-dependent RNA polymerase formed by TERT and the RMRP RNA
Maida, Y., Yasukawa, M., Furuuchi, M., Lassmann, T., Possemato, R., Okamoto, N., Kasim, V., Hayashizaki, Y., Hahn, W. C., & Masutomi, K. (2009) · Nature · doi:10.1038/nature08283 · Cited by 384
Telomerase directly regulates NF-κB-dependent transcription
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2621 · Cited by 378
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Self-citationSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A., Laborde, R. R., Lasho, T. L., Finke, C., Begna, K., Al-Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A., Kowalski, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 233
Self-citationTelomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Baerlocher, G. M., Oppliger Leibundgut, E., Ottmann, O. G., Spitzer, G., Odenike, O., McDevitt, M. A., Röth, A., Daskalakis, M., Burington, B., Stuart, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503479 · Cited by 200
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Tefferi, A. (2012) · Blood · doi:10.1182/blood-2011-11-395228 · Cited by 172
Self-citationImetelstat (GRN163L) - Telomerase-Based Cancer Therapy
Röth, A., Harley, C. B., & Baerlocher, G. M. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_16 · Cited by 125
For Better or Worse? Telomerase Inhibition and Cancer
de Lange, T., & Jacks, T. (1999) · Cell · doi:10.1016/s0092-8674(00)81955-8 · Cited by 119
Spliceosomal cleavage generates the 3′ end of telomerase RNA
Box, J. A., Bunch, J. T., Tang, W., & Baumann, P. (2008) · Nature · doi:10.1038/nature07584 · Cited by 100
Broséus, J., Alpermann, T., Wulfert, M., Florensa, L., Jeromin, S., Lippert, É., Rozman, M., Lifermann, F., Großmann, V., Haferlach, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.120 · Cited by 96
Telomerase RNA biogenesis involves sequential binding by Sm and Lsm complexes
Tang, W., Kannan, R., Blanchette, M., & Baumann, P. (2012) · Nature · doi:10.1038/nature10924 · Cited by 96
Targeting telomerase-expressing cancer cells
Ouellette, M. M., Wright, W. E., & Shay, J. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01279.x · Cited by 87
Tefferi, A., Finke, C. M., Lasho, T. L., Wassie, E. A., Knudson, R. A., Ketterling, R. P., Hanson, C. A., & Pardanani, A. D. (2013) · Leukemia · doi:10.1038/leu.2013.286 · Cited by 76
Self-citationSpanoudakis, E., Bazdiara, I., Pantelidou, D., Kotsianidis, Ι., Papadopoulos, V. P., Margaritis, D., Xanthopoulidis, G., Moustakidis, E., Mantzourani, S., Bourikas, G., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.07.042 · Cited by 31
Ruella, M., Salmoiraghi, S., Risso, A., Carobbio, A., Buttiglieri, S., Spatola, T., Sivera, P., Ricca, I., Barbui, T., Tarella, C., et al. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.03.007 · Cited by 26
Kannan, R., Hartnett, S., Voelker, R. B., Berglund, J. A., Staley, J. P., & Baumann, P. (2013) · Genes & Development · doi:10.1101/gad.212738.112 · Cited by 24
Cited by
Role of Telomeres and Telomerase in Aging and Cancer
Shay, J. W. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0062 · Cited by 668
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citationWolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30027-3 · Cited by 324
Metadata
- Authors
- Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., Gangat, N., Wang, X., & Pardanani, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-03
- Volume
- 373
- Issue
- 10
- Pages
- 908-919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1653629301
- Cited by
- 325
- References
- 34
- FWCI
- 20.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.